KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Interest & Investment Income (2016 - 2025)

Charles River Laboratories International has reported Interest & Investment Income over the past 17 years, most recently at $1.0 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 44.58% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $4.9 million, down 42.39%, while the annual FY2025 figure was $4.9 million, 42.39% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.0 million at Charles River Laboratories International, down from $1.4 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $3.0 million in Q2 2024 and troughed at $35000.0 in Q1 2021.
  • A 5-year average of $1.0 million and a median of $1.1 million in 2025 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: crashed 88.92% in 2021 and later skyrocketed 1025.41% in 2023.
  • Year by year, Interest & Investment Income stood at $309000.0 in 2021, then rose by 11.0% to $343000.0 in 2022, then soared by 363.85% to $1.6 million in 2023, then increased by 15.34% to $1.8 million in 2024, then plummeted by 44.58% to $1.0 million in 2025.
  • Business Quant data shows Interest & Investment Income for CRL at $1.0 million in Q4 2025, $1.4 million in Q3 2025, and $1.1 million in Q2 2025.